Abstract Library

#3853 Determining the resistance to somatostatin analogues in pheochromocytomas and paragangliomas

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) derived from chromaffin cells of the neural crest. Somatostatin analogues (SSAs) represent one of the pillars for NENs diagnosis/treatment due to the high density of somatostatin receptor (SSTs) in their membrane. However, although PPGLs share this characteristic, their response to SSAs is limited, being the reason underlying this unresponsiveness still unknown.

Conference:

Presenting Author:

Authors: García Vioque V, Blázquez-Encinas R, Moreno Montilla M, Mangili F, Martínez Montes �,

Keywords: pheochromocytoma, paraganglioma, neuroendocrine tumor, somatostatin analogues, treatment resistance,

#3108 Challenges in primary neuroendocrine tumor identification

Introduction: ACTH secreting neuroendocrine tumors can be a pituitary adenoma, an ectopic tumor, or very rarely - pituitary carcinoma. The identification of the primary neuroendocrine tumor can be challenging or even unsuccessful.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Butkus M

Authors: Sereikaitė L, Butkus M, Jasinskaitė M, Žilaitienė B,

Keywords: cushing syndrome, metastatic neuroendocrine tumor, pituitary adenoma, pituitary carcinoma,

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#2233 Potential Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumors

Introduction: Prolonged biochemical remission after treatment with steroidogenesis inhibitors has been described in patients with Cushing’s syndrome due to ectopic adrenocorticotropin hormone (ACTH) production. Some studies have suggested antiproliferative and apoptotic effect of ketoconazole in human cancer cells.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Feelders R, Castaño J, Van Dungen R, Dogan-Oruc F,

Keywords: ACTH- and non-ACTH producing NETs, ketoconazole, somatostatin analogs, apoptosis, cytotoxicity,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,